Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants (COSTAN)

This study has been terminated.
(Due to on-going enrollment challenges)
Information provided by (Responsible Party):
Biogen Identifier:
First received: October 11, 2012
Last updated: January 8, 2016
Last verified: December 2015
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: January 2018
  Estimated Primary Completion Date: October 2017 (Final data collection date for primary outcome measure)